(Q33367641)

26 July 2017

title

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree (English)

1 reference

26 July 2017

0 references

Serena Di Cosimo

3

0 references

Emilio Bria

object named as

Emilio Bria

4

0 references

Giuseppe Maria Ettorre

object named as

Giuseppe Maria Ettorre

8

0 references

Diana Giannarelli

object named as

Diana Giannarelli

10

0 references

author name string

Alain Gelibter

1

1 reference

26 July 2017

Paola Malaguti

2

1 reference

26 July 2017

Enzo Maria Ruggeri

5

1 reference

26 July 2017

Paolo Carlini

6

1 reference

26 July 2017

Fabio Carboni

7

1 reference

26 July 2017

Mario Pellicciotta

9

1 reference

26 July 2017

Edmondo Terzoli

11

1 reference

26 July 2017

Francesco Cognetti

12

1 reference

26 July 2017

Michele Milella

13

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

104

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

1237-1245

1 reference

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

A phase II study of gemcitabine in gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Advanced pancreatic cancer: is there a role for combination therapy?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

New applications of gemcitabine and future directions in the management of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21286

7 January 2021

Identifiers

DOI

10.1002/CNCR.21286

1 reference

26 July 2017

1 reference